Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | TOP1 | P11387 | 2/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231750 | 0.81 | ASIC3 (0.45) | RAB9ANPC1MEN1KMT2AATM | |
| SCHEMBL4599566 | 0.80 | RAB9A (0.40) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL5534502 | 0.80 | KMT2A (0.40) | RAB9ANPC1MEN1KMT2ATGFBR1 | |
| SCHEMBL4590373 | 0.80 | L3MBTL1 (0.42) | RAB9ANPC1MEN1KMT2ATGFBR1 | |
| SCHEMBL9699617 | 0.80 | MAPT (0.47) | RAB9ANPC1MEN1KMT2AATM | |
| SCHEMBL2750917 | 0.80 | GRM5 (0.38) | — | |
| SCHEMBL2753679 | 0.79 | RAB9A (0.47) | RAB9ANPC1TGFBR1TOP1ALDH1A1 | |
| SCHEMBL16719564 | 0.79 | KMO (0.45) | MEN1KMT2AFYNALDH1A1KDM4E | |
| SCHEMBL2184027 | 0.79 | KIF11 (0.47) | MEN1KMT2ATGFBR1TOP1KDM4E | |
| SCHEMBL606773 | 0.79 | LMNA (0.42) | RAB9ANPC1KMT2AFYNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284644-A1 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3747888-A1 | NITROGENATED HETEROCYCLIC AMIDE COMPOUND, AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco Inc. (JP) | 2020-12-09 | — | — | EP | disclosed |
| US-10800784-B2 | Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2020-10-13 | — | — | US | disclosed |
| WO-2019151274-A1 | NITROGENATED HETEROCYCLIC AMIDE COMPOUND, AND USE THEREOF FOR MEDICAL PURPOSES | 日本たばこ産業株式会社 | 2019-08-08 | — | — | WO | disclosed |
| CN-108290881-A | Therapeutic compounds and methods of use thereof | 健泰科生物技术公司 | 2018-07-17 | — | — | CN | disclosed |
| EP-1909775-A2 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | Onconova Therapeutics, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007016201-A2 | FORMULATION OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-5145858-A | Antiinflammatory | SMITHKLINE BEECHAM CORP. (US) | 1992-09-08 | — | — | US | disclosed |
| US-5134150-A | Administering diaryl-substituted imidazothiazoles; antiarthritic agents | SMITHKLINE BEECHAM CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
| US-5002941-A | Antiarthritic agents, arachidonic acid metabolism | SMITHKLINE BEECHAM CORPORATION (US) | 1991-03-26 | — | — | US | disclosed |
| CN-1032011-A | Pyrrolo-imidazoles and imidazopyridine and application thereof | SMITHKLINE BECKMAN CORP (US) | 1989-03-29 | — | — | CN | disclosed |
| US-4780470-A | WITH 4,5-DIALKYL-2(SUBSTITUTED)IMIDAZOLE | SMITHKLINE BECKMAN CORPORATION (US) | 1988-10-25 | — | — | US | disclosed |
| US-4751310-A | Inhibition of the 5-lipoxygenase pathway | SMITHKLINE BECKMAN CORPORATION (US) | 1988-06-14 | — | — | US | disclosed |
| US-4719218-A | ENZYME INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| CN-86108538-A | The inhibition of 5-lipoxygenase pathway | — | 1987-07-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800784-B2 | Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof | IDH2, PC, FH | RAB9A 2831/4885NPC1 428/4885MEN1 1012/4885 |
| US-20210284644-A1 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | IDH2, PC, FH | RAB9A 2831/4885NPC1 428/4885MEN1 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.